What diseases are nirogacestat indicated for?

Nirogacestat is a highly selective gamma-secretase inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of a rare disease - progressive desmoid tumor, or aggressive fibromatosis. Although this disease is a benign soft tissue tumor, it has a serious impact on patients' quality of life due to its aggressive growth, high recurrence rate, and strong compression of important organs. Nilogastat effectively inhibits tumor growth by blocking the activation of the Notch signaling pathway. It is currently the first targeted drug approved in the world for the systemic treatment of desmoid tumors.

Judging from the current instructions and research directions, its indications are mainly focused on the following aspects: first, adult patients with desmoid tumors who require systemic treatment, especially those with high surgical risks, local recurrence or difficulty in resection. Since this type of tumor has limited response to chemotherapy and radiotherapy, it is difficult to control the progression of the disease with traditional treatment methods. Therefore, nilogacestat provides an effective non-surgical treatment method, which is especially suitable for individuals who want to control the development of lesions for a long time.

In addition, nilogalstat is also exploring other indications in multiple ongoing clinical studies, including tumors related to abnormal Notch signaling. For example, in certain types of tumors such as breast cancer, multiple myeloma, and pancreatic cancer, Notch pathway abnormalities are considered to be one of the driving factors. Researchers are evaluating the synergistic anti-tumor effect of nilogalstat in combination with other drugs. Although these indications have not yet been officially approved, early studies have shown certain efficacy and application prospects.

It is worth noting that the indications of nirogacestat are based on the molecular mechanism of tumors, and molecular testing is required to confirm whether the lesions are related toγ-secretase. In the future personalized medical system, the use of this drug will rely more on accurate genetic diagnosis support.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html